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functions as a recycling mechanism to prevent degradation and
extend the half-life of IgG and albumin in the circulation.
Several FcRn inhibitors selectively targeting IgG recycling are
now moving rapidly toward clinical practice in neurology and
hematology. These molecules accelerate the destruction of IgG,
reducing pathogenic IgG and IgG immune complexes, with no
anticipated effects on IgA, IgM, IgE, complement, plasma cells,
B cells, or other cells of the innate or adaptive immune systems.
FcRn inhibitors have potential for future use in a much wider
variety of antibody-mediated autoimmune diseases. Given the
imminent clinical use, potential for broader utility, and novel
mechanism of action of FcRn inhibitors, here we review data
from 4 main sources: (a) currently available activity, safety, and
mechanism-of-action data from clinical trials of FcRn
inhibitors; (b) other procedures and treatments that also
remove IgG (plasma donation, plasma exchange,
immunoadsorption); (c) diseases resulting in loss of IgG; and (d)
primary immunodeficiencies with potential mechanistic
similarities to those induced by FcRn inhibitors. These data
have been evaluated to provide practical considerations for the
assessment, monitoring, and reduction of any potential infection
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Autoantibody-mediated autoimmune diseases can result in
tissue damage through IgG immune complex (IC) deposition1,2 or
via monomeric pathogenic autoantibodies, which bind directly to
target structures and induce damage through complement
activation and/or recruitment of inflammatory phagocytes.2-7
Current therapeutic strategies for the treatment of chronic
autoantibody-mediated diseases consist of reducing antibody
production by immunosuppression or B-cell–targeting drugs,
and removal of autoantibodies and IC via plasma exchange
(PLEX) or immunoadsorption (IA).8-10 Alternatively, for
monomeric IgG-mediated diseases, immunomodulatory
high-dose intravenous immunoglobulin (IVIg) therapy acts via
a number of mechanisms including increased catabolism of
autoantibodies via the neonatal fragment crystallizable (Fc)
receptor (FcRn), cytokine neutralization, blockade of activating
Fc-gamma receptors (FcgRs), or inhibition of autoantibodies by
binding of natural anti-idiotypes11,12 (see review by Shock
et al13 in this issue).
In many regions, supply and cost of IVIg are important factors.
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patients requiring IgG replacement therapy (IgRT) for treatment
of antibody deficiencies, and the expanding use of immunomod-
ulatory high-dose IVIg (on- and off-label) in the context of a
worldwide plasma shortage.14-16
IgG has one of the longest half-lives of serum proteins,
sustained by a specialized recycling pathway involving FcRn
(see Patel and Bussel17 review in this issue). FcRn is predomi-
nantly expressed on the endothelium, but has also been detected
in a diverse range of tissues and cell types.2 Because recycling
is the principal mechanism for maintaining a high serum level
of IgG (and albumin), modulation of this pathway by blockingY
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sh to acknowledge Jared Travers, MD, PhD, for preparing theFcRn is an attractive mechanism for the reduction of pathogenic
IgG autoantibodies. Inhibition of FcRn accelerates destruction of
IgG via lysosomal degradation. Using this targetedmechanism to
reduce tissue and serum concentrations of IgG has the potential to
provide significant therapeutic benefit for patients with both
monomeric and IC IgG autoantibody-mediated diseases.18-21
Should these therapies prove successful, they will provide an
alternative to high-dose IVIg and PLEX, reducing treatment
burden on health care systems and patients. FcRn inhibitors
currently in clinical trials include efgartigimod,20,22,23
rozanolixizumab,19,21,24 nipocalimab (M281),25 and orilanoli-
mab (SYNT001)18; additional FcRn inhibitors in development
include IMVT-1401/RVT-1401, CSL730/M230, and ABY-039
(see Patel and Bussel17 for further details).
In the absence of large data sets or long-term exposure to FcRn
inhibitors, this review aimed to define the immunologic impact of
decreasing levels of IgG through FcRn inhibitors. Furthermore,
we will review procedures and treatments that also remove IgG
(plasma donation, PLEX, and IA), diseases resulting in loss of
IgG, and genetic disorders with potential mechanistic similarities
to those of FcRn inhibitors, to better understand the risk of
infection associated with this novel class of drugs currently in
development. Finally, we aim to provide practical considerations
on assessment, monitoring, and precautions necessary to ensure
adequate humoral immunity in patients receiving an FcRn
inhibitor (postapproval) in various clinical scenarios.ACTIVITY AND SAFETY OF FcRn INHIBITORS IN
DISEASE SETTINGS
Efgartigimod, currently in phase 3 trials for generalized
myasthenia gravis (MG) and immune thrombocytopenia (ITP),
is a monoclonal IgG1 Fc fragment that has been mutated at 5
residues to increase its affinity for FcRn at both physiologic and
acidic pH.20 In a phase 2 randomized, placebo-controlled study
in 24 patients with MG (see Table E1 in this article’s Online
Repository at www.jacionline.org),20 following 4 once-weekly
(QW) intravenous (IV) administrations of 10 mg/kg efgartigi-
mod, mean maximum reductions in serum IgG of 70.7% from
baselinewere observed 1week after the final infusion. ReductionsIMMUNOGENICITY: The ability of a foreign substance to elicit an
immune response.
LYSOSOMAL DEGRADATION: The digestion of macromolecules,
including proteins, nucleic acids, lipids, and oligosaccharides, into their
building block molecules within intracellular lysosomes.
OPPORTUNISTIC INFECTIONS: Microbial infections that exhibit
increased frequency and severity in patients with compromised
immune systems.
PLASMA EXCHANGE: A procedure wherein blood plasma is removed
and exchangedwith either donor plasma or a plasma substitute, such as
albumin and saline.
PRIMARY IMMUNODEFICIENCY: Adisorder that results fromdeficiency
in the development and/or function of 1 or more components of the
immune system. To be considered primary, the immunodeficiencymust
not be secondary in nature, such as being a result of other disease, drug
treatment, or environmental exposure.
glossary.
J ALLERGY CLIN IMMUNOL
VOLUME 146, NUMBER 3
PETER ET AL 481in anti–acetylcholine receptor autoantibodies mirrored the
observed reductions in total IgG. Efficacy assessments using the
Quantitative MG (QMG), MG Activities of Daily Living, MG
Composite, and the revised MG Quality of Life 15-Item scales
consistently demonstrated that 75% of patients showed a rapid
disease improvement; improvements in QMG, MG Activities of
Daily Living, and MG Composite scores were sustained for the
duration of the study (through day 78).
Most frequently reported treatment-emergent adverse events
(TEAEs) in patients receiving efgartigimod were headache and
reduced white blood cell (WBC) counts, all of which were mild in
severity. Single TEAE reports considered possibly related to
efgartigimod and temporally associated with its administration
included decreases in total lymphocyte counts, T lymphocytes
and B lymphocytes, and monocytes, and an increase in neutrophil
counts (Table I).18-25 Hematologic changes (ie, abnormal
differential WBC counts) observed in 3 patients following
treatment with efgartigimod were mild and asymptomatic, and
most likely explained by concomitant use of immunosuppres-
sants. However, the first-in-human (FIH) study of efgartigimod23
also reported abnormal differentialWBC counts (mild decrease in
CD8, CD3, CD56, CD4, and CD19 lymphocyte counts) after
receipt of the drug (3 of 4 healthy volunteers who received 25
mg/kg and 4 of 4 who received 50 mg/kg).
Data from a phase 2 trial of efgartigimod in adults with primary
ITP reported clinically relevant increases in platelet counts with
associated decreases in IgG levels.22 Patients were randomized to
receive 4 QW doses of placebo (n 5 12), or IV efgartigimod
5 mg/kg (n5 13), or 10 mg/kg (n5 13), with a total of 21 weeks’
follow-up. Patients who experienced a relapse during the
follow-up period (platelet count, <30 3 109) had the option to
enroll in a 1-year open-label extension (Table E1) during which
they received efgartigimod 10 mg/kg QW for 4 weeks. In patients
treated with IV efgartigimod 10 mg/kg, a maximum reduction in
total serum IgG of 60% to 64% was achieved by day 25 (Table I),
with levels returning to baseline over the first part of the study
(80 days). Every patient achieved a decrease in all IgG subclasses;
antiplatelet autoantibodies were identified in all patients and were
reduced by treatment with efgartigimod. In patients receiving IV
efgartigimod 10 mg/kg, platelet counts rose from a mean of less
than 20 3 109/L at baseline to approximately 40 3 109/L at the
end of the treatment phase. During the main part of the study, a
platelet count of greater than or equal to 503 109/L was achieved
by a similar number of patients in the placebo group as in the
combined efgartigimod 5 mg/kg and 10 mg/kg groups (54%
and 50%, respectively). However, 46% of patients receiving
efgartigimod reached this threshold on at least 2 occasions
(25% placebo) and 39% maintained counts at or over
this threshold for more than 10 cumulative days (0% placebo);
42% achieved a platelet count of greater than or equal to
100 3 109/L (8% placebo).
Efgartigimod was well tolerated over the full duration of the
study, with no dose-related safety observations, no increased risk
of infection versus placebo, and a safety profile consistent with
previous FIH and MG studies. Changes in serum albumin were
similar between placebo and efgartigimod groups, mostly within
610% to 15% of baseline, and changes were not considered
clinically relevant, suggesting that efgartigimod does not interfere
with albumin binding22 (Table I).
A recent study explored the consequences of engineering the
Fc region of IgG1, thus manipulating the FcRn-IgG1 interactionon Fc effector function.26 All 4 recombinant human IgG1 variants,
one of which (MST/HN) carried the same 5 point mutations as
efgartigimod (M252Y, S254T, T256E, H433K, N434F23),
markedly reduced binding to classical FcgRs. Three of the 4
variants (includingMST/HN) demonstrated significantly reduced
binding to complement factor C1q. Reductions in FcgRs and C1q
binding limited the ability of these human IgG1 variants to
activate antibody-dependent mechanisms such as cell-mediated
cytotoxicity, cellular phagocytosis, and complement-mediated
cell lysis. Interestingly, previous successful attempts to treat acute
childhood ITP with infusions of unmutated Fcg fragments
suggested a predominant blocking action on classical FcgRs on
mononuclear phagocytes.27 To our knowledge, the effects of
efgartigimod on classical FcgRs- and C1q-mediated functions
have not been published and more information is needed to
determine whether efgartigimod, besides inhibiting FcRn, has a
significant effect on FcgRs and C1q binding.
Rozanolixizumab, currently in phase 3 trials for MG and ITP
and a phase 2 trial for chronic inflammatory demyelinating
polyneuropathy (CIDP), is a subcutaneously (SC) infused
humanized IgG4 mAb that binds to human FcRn, selectively
inhibiting IgG binding without affecting albumin.24 In a phase
2 placebo-controlled clinical trial, 43 patients with generalized
MG were randomized equally to 3 QW SC infusions of
rozanolixizumab 7 mg/kg or placebo in period 1; in period 2,
patients were rerandomized to 3 additional QW SC infusions of
rozanolixizumab 7 mg/kg or 4 mg/kg (Table E1).19 Treatment
with rozanolixizumab 7 mg/kg resulted in rapid reductions in
both total IgG and anti–acetylcholine receptor autoantibody
concentrations, with a maximum decrease of approximately
68% observed in patients receiving SC rozanolixizumab
7 mg/kg/week throughout the study. Least-squares mean
differences between rozanolixizumab and placebo groups at day
29 were 20.7 (P 5 .221) for the QMG score, 21.4 (P 5 .036)
for the MG Activities of Daily Living score, and 21.8
(P 5 .089) for the MG Composite score. The most frequently
reported TEAE in patients receiving rozanolixizumab was
headache. The investigators concluded that despite not meeting
the primary end point of change from baseline in the QMG score
at day 29, proof of concept was achieved on the basis of clinically
meaningful improvements in MG outcomes and reductions in
autoantibody titers.19
A phase 2 open-label, multiple-dose clinical trial in 66 patients
with persistent/chronic primary ITP21 assessed the effect of
different dose schedules of SC rozanolixizumab for a similar total
exposure of 15 to 21 mg/kg (Table E1). The primary objectives
were safety and tolerability; secondary objectives were efficacy
(change in platelet count) and pharmacodynamics (change in total
IgG). The most common TEAEs were headache, diarrhea, and
vomiting (all mild to moderate in intensity); no serious infections
were observed. There were dose-dependent increases in platelet
counts: by day 8, a platelet count of greater than or equal to
50 3 109/L was achieved by 54% and 58% of patients in the
20 mg/kg and 15 mg/kg single-dose groups, respectively, with
median peak counts exceeding 100 3 109/L in both groups.
Dose-dependent decreases in serum IgG concentration were
observed by day 8, with the 20 mg/kg (n5 12) single-dose group
achieving its nadir of a 60% mean change from baseline in
total serum IgG at this time point, whereas the 5 3 4 mg/kg
(n5 15) group achieved its nadir of 43.6% change from baseline
on day 29.
TABLE I. Summary of IgG, albumin, adverse event, and infection data for reported clinical trials of FcRn inhibitors
Indication N
Intervention
and
comparator
Duration of
follow-up
Mean
maximum
reduction
in IgG (%)
Impact on
albumin
TEAEs of
interest (%)
Reported
infections
Efgartigimod (IV)
MG20
(NCT02965573)
24 d 10 mg/kg
QW 3 4
d Placebo
8 wk 70.7 week 4 Not reported d Headache
d Nausea
d Diarrhea
d Abdominal pain
d Total lymphocyte
count decrease
d T- and
B-lymphocyte
decrease
d Monocyte count
decrease
d Neutrophil count
increase
33.3
8.3
8.3
8.3
16.7
16.7
16.7
16.7
Herpes zoster:
1 efgartigimod-
treated patient
(also seen in
SoC treatment
with prednisone
and
mycophenolate
mofetil)
ITP22
(NCT03102593)
38 d 5 mg/kg
QW 3 4
d 10 mg/kg
QW 3 4
d Placebo
21 wk 60.4 D25
63.7 D25
Similar between
groups
and within
610%-15%
baseline
d Vomiting
(5 mg/kg
group only)
d Headache
(10 mg/kg
group only)
15.4
7.7
1 pneumonia
(deemed
unrelated to
efgartigimod
treatment);
no apparent
increased risk
of infection
FIH23
(NCT03457649)
MAD:
32
d 10 mg/kg
Q4D 3 6
d 10 mg/kg
QW 3 4
d 25 mg/kg
QW 3 4
d Placebo
58-59 d 78.5 D24 Emax
73.0 D24 Emax
77.7 D24 Emax
No significant
decrease
d Headache
d Abdominal
discomfort
d In the SAD
part of the
study, abnormal
differential WBC
count was reported
by 3 of 4 healthy
volunteers receiving
25 mg/kg and 4 of 4
receiving 50 mg/kg
n 5 4
n 5 1
None
Rozanolixizumab (SC)
MG19
(NCT03052751)
43 Period 1 (D1-29):
d 7 mg/kg
QW 3 3
d Placebo
Period 2 (D29-43):
d 4 mg/kg
QW 3 3
d 7 mg/kg
QW 3 3
d Placebo
55 d 68 D50 in
patients
receiving
7 mg/kg
throughout
the study
Not reported d Headache 57.1 Not reported
ITP21
(NCT02718716)
66 d 15 mg/kg 3 1
d 20 mg/kg 3 1
d 4 mg/kg 3
5 QW
d 7 mg/kg 3
3 QW
d 10 mg/kg 3
2 QW
8 wk 60 D8 for
single-dose
20 mg/kg
Not reported d Headache
d Diarrhea
d Vomiting
39.4
12.1
9.1
No serious
infections
(Continued)
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Indication N
Intervention
and
comparator
Duration of
follow-up
Mean
maximum
reduction
in IgG (%)
Impact on
albumin
TEAEs of
interest (%)
Reported
infections
FIH24
(NCT02220153)
SAD
SC: 24
d 1 mg/kg
d 4 mg/kg
d 7 mg/kg
d Placebo
79 d 43.4 for
7 mg/kg D10
Modest decrease,
not significantly
different from
placebo
d Headache
d Nausea
d Diarrhea
d Vomiting
d Abdominal pain
27.8
0
16.7
11.1
5.6
Incidence of
treatment-related
infections was
lower in the
rozanolixizumab
total group
(13.9%) than
in the placebo
group (23.1%)
Nipocalimab (IV)
FIH25
(NCT02828046)
MAD:
16
d 15 mg/kg
QW 3 4
d 30 mg/kg
QW 3 4
d Placebo
Up to 14 wk D20*: 83 Emax
D24*: 84 Emax
Asymptomatic and
transient reduction
in total serum
protein and
albumin
d Headache
d Nausea
d Gastroenteritis
8.3
8.3
8.3
Incidence of
treatment-
emergent
infections and
infestations was
similar between
nipocalimab
(41.7%) and
placebo (50%)
groups
Orilanolimab (IV)
FIH18
(NCT03643627)
SAD:
31
d 1 mg/kg
d 3 mg/kg
d 10 mg/kg
d 30 mg/kg
d Placebo
27 d 46.21 median for
30 mg/kg dose
group within
5 d
No significant
changes
d Headache
d Nausea
d Diarrhea
d Abdominal pain
d Decreased appetite
34.8
4.3
4.3
4.3
4.3
Not reported
D, Day; Emax, maximum percentage reduction value; MAD, multiple ascending dose; Q4D, every 4 d; SAD, single ascending dose; SoC, standard of care.
For FIH studies, data are presented for multiple doses if available.
*Median time to Emax.
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IgG1 anti-FcRn antibody engineered to have no Fc effector
potential (no C1q binding, and no binding to activating FcgR),
and orilanolimab (SYNT001), a humanized IgG4k mAb,
are 2 additional FcRn inhibitors with published FIH data18,25
(Table I). Nipocalimab is currently in phase 2 trials for autoim-
mune hemolytic anemia, hemolytic disease of the fetus and
newborn, and MG. The orilanolimab FIH study assessed the
impact on C1q-associated circulating IgG ICs measured by the
MicroVue CIC-C1q EIA Kit, in addition to demonstrating reduc-
tions in serum IgG. The investigators report that administration of
orilanolimab to 31 healthy male volunteers resulted in significant
dose-dependent reductions in circulating ICs, and ex vivo, orila-
nolimab inhibited the ability of IgG ICs to induce secretion of
innate inflammatory cytokines by human peripheral blood leuko-
cytes.18 Whether these promising initial findings translate into
clinically meaningful therapeutic effects in patients with IgG
IC-mediated disease remains to be seen.
Areas where further data are required to contribute to our
understanding of the impact of FcRn inhibitors on immune
function remain, in addition to data sets anticipated from
unpublished phase 2 studies and forthcoming phase 3 trials. It
would be of interest to understand details of specific antibody
titers before and after inhibition of FcRn, booster responses
during treatment, and responses to neoantigens (eg, hepatitis A or
rabies vaccine). The impact of dose and route of administration on
safety, efficacy, and patient satisfaction with treatment also needs
to be evaluated. As patient numbers increase, analyses ofbacterial, viral, and fungal infections relative to placebo groups
should become possible, as should understanding the impact of
previous and concomitant therapies on changes in serum IgG and
risks of infection. Further studies should also shed light on the
impact of FcRn inhibitors on antigen presentation and follicular
dendritic cells, which will be relevant to the understanding of
potential FcRn inhibitor–associated infection risk. Finally, more
information will emerge on interindividual or age-dependent
variability in FcRn expression and, in turn, how this affects
response to FcRn inhibitors.THE MECHANISTIC BASIS OF FcRn INHIBITION:
POTENTIAL IMPACT ON IMMUNE FUNCTION
Current evidence shows that inhibition of FcRn selectively
reduces serum IgG, with no relevant reductions in IgM, IgA, IgE,
or albumin18,23-25 (Table I). Reduction in IgG is transient and
reversible, with mean maximum reductions in serum IgG of
45% to 85% from baseline, returning to near-baseline levels 50
to 57 days (28 days for orilanolimab) after single doses,18,24,25
and 50 to 80 days after multiple doses,20,22,23,25 indicating that
function of the memory B- and plasma-cell compartments
remains unaffected by inhibition of FcRn (Table I). During
clinical trials of FcRn inhibitors, no rebound effect on levels of
total IgG has been observed; for specific antibodies and
autoantibodies, rebound is unknown and considered unlikely.
Any differential impact of FcRn inhibitors on reductions in IgG
subclasses is of interest due to their potential utility for the
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28 An FIH study of efgartigimod
reported that following administration of both single and multiple
doses of efgartigimod, reductions in IgG1-3 followed a similar
pattern, with slightly smaller reductions observed for IgG4.
23
This pattern of lower reductions for IgG4 in comparison with
IgG1-3 was also observed in the phase 2 studies of efgartigi-
mod,20,22 suggesting perhaps less efficient FcRn blockade by ef-
gartigimod (a mutated Fc portion of IgG1) for IgG4. In contrast,
FIH studies of rozanolixizumab and orilanolimab both reported
that administration of single doses resulted in dose-dependent re-
ductions in IgG1-4, with the most pronounced changes seen for
IgG3.
18,24 A fourth phase 1 study found that each IgG subclass ex-
hibited similar decreases in serum levels after the administration
of single doses of nipocalimab; this observation was highly
consistent across subjects.25 Although a detailed structure-
function analysis is beyond the scope of this review, factors
such as half-life of subclasses, gamma marker (Gm) allotypes,
and binding characteristics to FcRn deserve some mention.
Histidine at position 435 (H435) provides for optimal FcRn-
IgG binding and a long half-life (21 days). IgG1, IgG2, and
IgG4 carry the H435 variant, whereas an arginine at position
435 (R435) is more common in the IgG3 subclass, leading to
reduced binding affinity for FcRn, a shortened half-life (8
days), and reduced transplacental IgG3 transfer.
29,30 Interestingly,
the H435 variant of IgG3 has a different prevalence among
Europeans (1%), Asians (10%-25%) and Africans (30%-60%),
an observation that has been found to be important in the transpla-
cental transfer of IgG3 antibodies in antimalarial immunity.
29,31
Similarly, the high number of codominantly inherited Gm allo-
types in the IGHG3 locus (13 of all 20 Gm allotypes reside
here) suggests a strong functional selection pressure in this part
of the genome.32 Whether differences in IgG3 H435/R435 and
Gm3 allotype markers (such as G3m5, G3m6, G3m15, G3m16,
G3m21 or G3m24, all encoded by 1 or several IGHG3 alleles)
could influence its blockade through FcRn inhibitors and the
clinical relevance of such a potential effect requires monitoring.
The main TEAEs reported to date appear to be gastrointestinal
(GI) disturbances and headache—predominantly mild to moder-
ate in severity, and, in the case of headache, manageable with
standard therapies. More data are needed to clarify the effect of
FcRn inhibitors on lymphocyte, monocyte, and neutrophil counts
given the effects reported in the phase 1 FIH23 and phase 2 trial of
efgartigimod in MG24 and ITP.20,22 As with all immunomodula-
tory therapies, there is a concern of increased risk of infection,
although there is no evidence of increased infections for FcRn in-
hibitors reported so far. However, data are still limited, and
increased rate of infection is perhaps the greatest theoretical
risk associated with these new therapies. By inducing transient
reduction in IgG, inhibition of FcRn has interesting parallels
with several primary and secondary immunodeficiencies as well
as procedures that reduce serum IgG. Assessing data from these
examples may aid our understanding of the immunologic impact
of FcRn inhibition and thus the potential risk of infection.Hypogammaglobulinemia and infection risk
Increasing the rate of IgG removal via therapeutic inhibition of
FcRn does not distinguish between pathogenic and nonpatho-
genic IgG and could be considered a type of novel secondary
immunodeficiency (SID) (for overview, see Fig E1 in this article’s
Online Repository at www.jacionline.org).33 Although SID canresult in increased risk of infection, potential severity varies
widely, ranging from a modest increase in mild infections to a
more serious profile, including opportunistic pathogens.33 In pa-
tients with autoimmune diseases, antibody deficiencies can be
multifactorial, from underlying disease processes and subsequent
treatments. Patients who experience loss of IgG while antibody
production and quality remain unaltered (eg, renal or GI losses,
or antibody removal by PLEX) retain specific antibody produc-
tion, and have a lower infection risk and less severe symptoms
compared with patients with genetic disorders that result in global
deficiency of antibody production.33 Patients with genetic
disorders resulting in low IgG who retain normal IgA and/or
IgM levels may experience a more benign infection and
complication profile.34-38 SID with a high risk of infections
may occur, particularly when antibody production is impaired
such as in lymphoid malignancies33,39,40 or prolonged treatment
with B-cell–depleting therapies (eg, rituximab).41-46
To assess the infection risk in SID or after therapeutic removal
of immunoglobulin, it is important to consider which
immunoglobulin class(es) has been reduced, where and how
they function, and the mechanism and degree of reduction
achieved.33 Although FcRn is key to homeostatic regulation of
both IgG and albumin, it does not bind to the other immuno-
globulin classes (Fig 1). As observed in the FcRn inhibitors trials
to date, inhibition of FcRnwould be expected to induce a transient
reduction in IgG with no relevant loss of IgM, IgA, or IgE. FcRn
binds to albumin and IgG at 2 distinct sites in its a1 and a2
domain, respectively,47 FcRn inhibitors bind only to the a2
domain; therefore, specific FcRn inhibitors should not impact
serum albumin concentrations.
Inhibition of FcRn is not expected to affect plasma cells, B-cell
repertoire, or memory B cells, or to interferewith other cells of the
innate and adaptive immune systems, or complement. Because of
its discrete mechanism of action, FcRn inhibition is less likely to
be associatedwith increased risk of infection compared with other
immunomodulators such as glucocorticoids or rituximab, and
unlikely to lead to opportunistic infections with intracellular
pathogens, particularly those requiring granulomatous
inflammation for control (eg, mycobacteria, fungi). However, as
a result of the selective loss of IgG, some recipients may be at
increased risk for certain sinopulmonary infections, including
those caused by respiratory viruses, Hemophilus influenzae,
Streptococcus pneumoniae, andMoraxella catarrhalis. Inhibition
of FcRn results in a selective and reversible reduction of IgG that
would be predicted to have a lower risk of infection than the
impaired production of multiple immunoglobulin classes that
results from some genetic disorders. We will therefore also
consider infection data associated with procedures that remove
IgG, diseases that result in loss of IgG, and genetic disorders
with mechanistic similarities to inhibition of FcRn.WHAT CAN WE LEARN FROM OTHER CONDITIONS
AND THERAPIES?
Procedures that remove IgG
Plasma donation, PLEX, and IA all involve removal of blood
components with greater or lesser degrees of selectivity for IgG
(Table II).18,23-25,48-64 These procedures result in the reduction of
existing antibodies, while leaving production of immunoglobu-
lins by plasma cells intact (Table II). Levels of serum proteins,
Isotype Fc receptor binding Distribution and  site of function
IgA FcαRI
Fcα/µR
PIgR
Epithelial surfaces in
the gastrointestinal
and respiratory tracts
IgE FcεRI
FcεRII
Mast cells and basophils 
beneath the skin and 
mucosa and along blood 
vessels in connective 
tissue; also, small 
quantities in blood and 
extravascular fluid
IgG FcγRI
FcγRIIA, B, C
FcγRIIIA, B
FcRn
Blood, lymph and 
extravascular fluid
IgM FcµR
Fcα/µR
Blood; also small  
quantities in lymph
FIG 1. Distribution and function of immunoglobulin isotypes. PIgR, Polymeric immunoglobulin receptor.
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redistribution from the extracellular space.
Plasma donation is perhaps the most common and least
documented in terms of understanding the impact on the immune
system and the subsequent infection risk. Plasma derivatives,
including IVIg and albumin, are derived by processing a large
number of pooled plasma donations.65,66 Apheresis plasma
donations are generally restricted to 400 to 900 mL/donation
(anticoagulant excluded) at a frequency of 13 to 104 donations
per individual per year,66 with data suggesting a 13% reduction
from baseline in donor serum IgG levels over the course of an
800 mL donation.48 A limited number of studies have prospec-
tively assessed the safety of long-term intensive plasmapheresis
on donors.49,67,68 Even with intensive plasmapheresis, there is
no evidence of reduced immune responses; donors have normal
IgG production and respond normally to antigenic stimulation
(Table II).
PLEX involves the removal of 1 to 1.5 plasma volumes (30 to
40 mL/kg) per exchange using centrifugation or filtration-based
devices, and replacing volumewith isotonic albumin or a mixture
of saline and albumin to avoid hypotension.51 The procedure
requires large-caliber venous access and may be associated with
cardiovascular disturbance; close monitoring of electrolytes is
also needed.51 Therapeutic effect is based on the removal of
circulating pathogenic immune factors, including autoantibodies
and ICs; however, nonpathogenic IgG, IgA, and IgM are also
removed, as well as complement components (Table II). PLEX
is predominantly used in the acute treatment of several
antibody-mediated disorders such as MG, lupus crisis,
Guillain-Barre syndrome, and pulmonary-renal syndrome.51
PLEX does not always provide clinical benefit in chronic
diseases,69 andmay not be themost effective or targeted approach
to the treatment of autoantibody-mediated diseases, because it
removes all circulating proteins. In addition, as IgG is distributed
throughout the extravascular space, its removal from serum byPLEX results in rapid redistribution back into the intravascular
space.69
IA is a therapeutic procedure for the specific removal of
proteins by passing separated plasma through an adsorption
column. Immunoglobulins can be targeted for removal through
binding to selected ligands on the backing matrix surface (mem-
branes or beads) of the adsorption column (Table II). Although IA
is effective for the treatment of pemphigus vulgaris70,71 and
CIDP,72,73 IA systems are used less frequently than PLEX for
the treatment of IgG autoantibody-mediated diseases, due to the
availability and complexity of the procedure, and regulatory
and economic differences between health care systems.51
The American Society for Apheresis, the American Academy
of Neurology, and other organizations have published guidelines
and commentaries for PLEX and IA,51,74,75 noting that side
effects and complications of PLEX and IA mostly relate to the
procedure itself.75,76 Both treatments are used in patients with a
range of heterogeneous disorders alongside varied previous ther-
apies and differing numbers of exchanges. Thus, teasing out the
specific impact on infection risk of using these procedures to re-
move serum proteins is challenging, with few studies assessing
the risk of infection for these procedures in patients with
antibody-mediated autoimmune diseases. Schmaldienst et al77
evaluated the infection risk of IA with and without IVIg
substitution. Overall, rates of infection were low and similar
between groups (IA 1 IVIg, 1.3 per patient-year, interquartile
range, 0-2; IA alone, 0.9 per patient-year, interquartile range,
0-2).77 In 2012, Som et al78 reported data for PLEX-related
complications from the Oklahoma thrombocytopenic
purpura-hemolytic uremic syndrome Registry, which provides
data from a population-based inception cohort of consecutive pa-
tients with a diagnosis of thrombocytopenic purpura or hemolytic
uremic syndrome. Over 15 years, the percentage of patients with
major complications attributed to PLEX decreased—because of
reduced frequency of catheter-related complications, rather than
TABLE II. Procedures and conditions causing excessive loss of antibodies
Procedure/
condition T cells B cells NK cells IgA IgM IgE IgG Albumin Infection risk References
Procedures that remove IgG
Plasma
donation
Normal humoral and cellular immunity Decreased
(Ab loss)
Normal or
reduced
No risk 48-50
PLEX Possible alterations
in lymphocyte
function due to
mechanical damage
Decreased (with
rapid recovery)
Decreased (with
rapid recovery)
Decreased
(Ab loss),
recovery
may be
delayed by
weeks
NR 51,52
IA Decreased (Ab loss). Dependent on the ligands used to
bind different Ig classes
NR 51
FcRn
inhibitors
Normal Normal Normal Normal Normal Normal Decreased
(Ab loss)
Normal
or modest
decrease
No increased risk
of infection
reported
18,23-25
Conditions that result in loss of IgG
Protein loss
d Renal loss
B Nephrotic
syndrome
T-cell
abnormalities
B-cell
abnormalities
NR NR Normal to
elevated
levels
NR Decreased
(Ab loss)
Decreased;
synthesis
may be
increased
Increased
susceptibility,
particularly to
bacterial
infections
53-55
d Gastrointestinal
loss*
Decreased Decreased NR Decreased Normal or
decreased
Normal Normal or
decreased
(Ab loss)
Reduced,
synthesis
normal
or increased
NR 56,57
d Fontan
procedure
Normal or
decreased
Normal Normal Variable Variable NR Decreased
(Ab loss)
Normal or
increased
Delayed clearance
of cutaneous
viral infections
58
CD55 deficiency Normal Normal Normal Decreased
(Ab loss)
Decreased
(Ab loss)
Decreased
(Ab loss)
Decreased
(Ab loss)
Decreased Recurrent
respiratory
infections
59
Genetic disorders resulting in the increased catabolism of IgG
d FcRn defect
B B2M deficiency
B Myotonic
dystrophy
Normal; altered
differentiation
of CD8 T cells
Decreased Decreased;
but
functionally
inactive
Normal to
elevated
Variable NR Decreased
(Ab loss)
Decreased Infections
include RTIs;
granulomatous
dermatitis;
recurrent otitis
media
60,61
62
d Glycosylation
type IIb
defect
B MOGS-CDG
Normal Normal or
increased
Normal Decreased (Ab loss)
Shortened half-life
of Igs due to a
glycosylation defect
Decreased because of
reduced half-life
of Igs
Normal Paradoxical
increased
resistance
to some viral
infections, due to
glycosylation
defects in viral
receptors and
viral envelope
(n 5 3 patients)
63,64
The literature was also assessed for changes to antigen-presenting cells, but no data were reported for this cell type in the articles cited.
Ab, Antibody; CDG, congenital disorders of glycosylation; MOGS, mannosyl-oligosaccharide glucosidase; NK, natural killer; NR, not reported; RTI, respiratory tract infection.
*Early onset inflammatory bowel disease caused by single gene defects associated with immune dysregulation.
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no mention of increased infection risk as a consequence of
hypogammaglobulinemia.78
Overall, PLEX and IA appear to be associatedwith a low risk of
infection, and infections that do occur are mainly associated with
venous access. In the case of PLEX, which removes IgA, IgM,complement, and other blood components in addition to IgG, the
low level of reported infections offers some reassurance regarding
the impact of procedures that leave antibody production intact. In
clinical practice, the use of these therapies and the duration and
degree of IgG reduction that can be realistically achieved may be
limited by their other side effects and the burden of treatment on
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inhibitors to reduce serum IgG while leaving all other serum
constituents intact, and without the associated risks with extended
venous access/central venous catheters, anticoagulants, and donor
blood products, would suggest a similar or lower infection risk
than with PLEX or IA.Diseases that result in loss of IgG
Further insights into the potential impact of FcRn inhibition on
risk of infection can be obtained from conditions associated with
loss of fully functional IgG (Table II).Nephrotic syndrome is typi-
cally associated with proteinuria, resulting in peripheral edema
and hypoalbuminemia due to increased glomerular permeability
caused by a number of primary and secondary glomerular dis-
eases.53 Because of its large molecular weight (150 kDa)
compared with albumin (70 kDa), only a subset of patients with
nephrotic syndrome experience loss of IgG. Nephrotic syndromes
with nonselective protein loss that includes IgG have less favor-
able prognoses than those with selective loss of small proteins,
because they frequently lead to tubulointerstitial damage and
decreased likelihood of remission.79 Patients with nephrotic
syndrome have increased susceptibility to infection due to
hypogammaglobulinemia, reduced complement activity, and
treatment-related (corticosteroids, immunosuppressive agents)
decrease in T-cell function,80 as well as increased risk of clotting
disorders and cellulitis due to peripheral edema (Table II).
Infections have been reported in up to 20% of adult patients,
with bacterial infections such as pneumonia and cellulitis being
the most common.53
Protein-losing enteropathy (PLE) can result in loss of all serum
proteins, including immunoglobulins, and sometimes WBC into
the gut lumen (Table II). PLE has been observed in a range of
GI and non-GI conditions including cardiac disease, liver disease,
and systemic lupus erythematosus, and, rarely, arises after the
Fontan procedure for single-ventricle congenital heart disease.56
Because albumin and IgG contribute to most of the total osmotic
effect of human serum, peripheral edema, ascites, and pleural
effusions are the most common clinical complications of PLE.
The loss of immunoglobulins and coagulation factors increases
the risk of bacterial infections and clotting disorders.81 The
Fontan procedure leads to increased central venous pressure,
hypogammaglobulinemia, and lymphopenia secondary to chronic
GI loss of lymph. However, severe bacterial infections are
infrequent and only a minority require IgRT.58
CD55 deficiency is an autosomal-recessive syndrome that re-
sults in hyperactivation of complement, angiopathic thrombosis,
and PLE. All patients described to date have normal lymphocyte
subsets and antibody production. The PLE-induced decrease in
IgA, IgM, IgG, IgE, and albumin is directly related to primary
intestinal lymphangiectasia, intestinal inflammation, and
thromboses (Table II).59 Five of 11 patients experienced
recurrent respiratory infections associated with hypogamma-
globulinemia; infections were reduced in 2 patients after
treatment with IVIg.59
Although patients with nephrotic syndrome, PLE, and CD55
deficiency have extensive protein loss in common, their antibody
production is normal, suggesting that most symptoms are
associated with protein loss. The infection susceptibility profiles
observed in these conditions are typically mild and limited to
sinopulmonary infections and cutaneous cellulitis, and are lessfrequent than in patients with abnormal antibody production. In
contrast to FcRn inhibitors, the protein loss in these conditions is
not limited to IgG but, depending on disease severity, can include
low- and high-molecular-weight proteins such as albumin, IgA,
IgM, IgG, IgE, and complement, as well as cellular elements.
Loss of albumin and associated peripheral edema is the dominant
risk factor for cellulitis, and therefore unlikely to be a concern for
treatment with FcRn inhibitors.Genetic disorders with mechanistic similarities to
inhibition of FcRn
The b2 microglobulin (B2M) gene is required for cell-surface
expression of nearly all members of the MHC-I family,
including FcRn. B2M deficiency has been described in 2 pairs
of siblings.60,61 Although the genetic mutations and subsequent
levels of B2M expression differed between the pairs of siblings,
all 4 patients had normal-to-high IgA levels, variable IgM levels,
and low serum albumin and IgG levels due to a lack of functional
FcRn (Table II). Because of its role in mediating cell-surface
expression of MHC-I molecules, the impact of B2M deficiency
was not limited to humoral immunity. The patients had a
complex immunodeficiency impacting both the innate and the
adaptive immune systems, characterized by altered differentia-
tion of CD8 T cells and a lack of functional natural killer cells.61
Clinically, patients presented with recurrent bacterial
respiratory tract infections, bronchiectasis, and inflammatory
skin lesions, all of varying severity, resembling transport
associated with antigen processing deficiency and other
MHC-I deficiencies.60,61
Myotonic dystrophy is an autosomal-dominant disorder charac-
terized by muscle weakness, myotonia, cataracts, and cardiac
conduction defects. Hypogammaglobulinemia is a lesser-known
symptom of myotonic dystrophy type 1, with patients typically
having low IgG1 and IgG3, with normal levels of IgM, IgA,
IgG2, IgG4, and albumin; patients retain the ability to produce
protective specific vaccine-related antibody titers (Table II).62 It
has previously been proposed that alterations to the FcRn receptor
in myotonic dystrophy type 1 lead to impaired recycling and
hypercatabolism of IgG.82 Although patients with myotonic
dystrophy type 1 and hypogammaglobulinemia have been
reported to experience increased infection risk, the resulting
burden of infection in these patients does not appear to correlate
directly with serum levels of IgG, and the mechanism by which
IgG levels are reduced remains unclear.62
Mannosyl-oligosaccharide glucosidase mutations represent 1
of more than 100 types of congenital disorders of glycosylation
identified to date and caused by defects in protein or lipid
glycosylation.63 N-glycosylation disorders such as mannosyl-
oligosaccharide glucosidase-congenital disorders of glycosyla-
tion result in intrinsic defects, affecting immunoglobulin structure
and stability, and can alter IgG function and half-life (Table II).83
Case studies of 6 patients have reported variable infection rates
and a complex influence on vaccine responses.63,64,84
B2M deficiency presents with a complex immunologic picture,
myotonic dystrophy, and mannosyl-oligosaccharide glucosidase-
congenital disorders of glycosylation selectively shorten the half-
life of IgGwithout impacting IgA, IgM, IgE, or other components
of the immune system. In addition, in each of these conditions,
reductions in IgG do not appear to correlate directly with infection
risk.
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Inhibition of FcRn reduces both pathogenic and nonpathogenic
IgG (but does not change the production or quality of IgG),
without affecting other components of the innate or adaptive
immune systems. Based on the multiple lines of evidence
reviewed, it would be expected that patients receiving an FcRn
inhibitor will have limited risk of increased infection. Here, we
provide our considerations for clinicians in terms of diagnostic
assessments, monitoring of patients, and vaccination, before and
during FcRn inhibition. These principles are based on the limited
currently available clinical evidence and are driven by theoretical
and scientific deliberations, because FcRn inhibitors are still in
clinical development and yet to be licensed for use. We expect
these principles to evolve as clinical trial data and real-world
evidence emerge, and in accordance with future individual drug
labels.Diagnostic assessments before FcRn inhibition
Establish any possible preexisting risks for infection from the
clinical history and with the following assessments:
d WBC count with differential; C-reactive protein, liver, and
renal function profiles; serum albumin; and IgG, IgA, and
IgM.
Establish presence of hepatitis B virus (HBV), hepatitis C virus,
and/or HIV in patients at risk for infection:
d Serologic and/or PCR screening may need to be performed.
d Capacity for seroconversion may be affected by a primary
immune defect or by previous therapies; therefore, assess-
ment of the corresponding viral load (VL) may be the
preferred approach.B Where possible, storage of serum for future analysis
should be considered, because serology testing may be
less reliable after treatment.In patients with a family history and/or clinical suspicion of pri-
mary immunodeficiency or SID, additional testing beyond
immunoglobulin levels could be considered—including (but
not limited to) T-, B-, and natural killer–cell enumeration and
subset differentiation.
These immunologic tests provide a baseline assessment of the
patient to facilitate interpretation of potential changes in
these parameters, which is useful because patients with
primary immunodeficiency may present with autoimmune
complications.Prophylactic antibiotics before FcRn inhibition
Routine antibiotic prophylaxis for patients before or during
FcRn inhibition was not recommended for the clinical trials.
d Specific approaches may be required for some underlying
conditions (eg, CD41 T lymphopenia, splenectomy, or
multilobar bronchiectasis) or if there is a burden of infec-
tion before initiation of an FcRn inhibitor.
Vaccination
The immunogenicity of vaccines is not currently expected to
be compromised by FcRn inhibition. However, the ability to
respond to vaccines may be impaired because of other recent
immunosuppressant therapy.For FcRn inhibition in treatment-naive patients, we would
recommend the following:d Recombinant or inactive vaccinations be up-to-date more
than or 2 to 4 weeks before commencing treatment, al-
lowing time for adaptive immunity to develop.
d Live attenuated vaccines be administered more than or 8
weeks before initiating an FcRn inhibitor, to ensure
enough time for clearance of vaccine-associated viremia.
B Live attenuated vaccines are generally contraindicated
in patients with proven or suspected immunodefi-
ciency, because of the potential for vaccine-related
complications.For patients already receiving an FcRn inhibitor:d There is currently no evidence against administering in-
activated and recombinant vaccines.
d Kinetics of IgG restoration, following single or multiple
dosing of an FcRn inhibitor, suggest that vaccines should
be given 2 months or more after the last dose, and more
than or 2 to 4 weeks before the next.
d Inactivated influenza vaccine should be administered
annually, with the timing based on the scenarios
described above.The safety of live attenuated vaccines in patients receiving an
FcRn inhibitor is currently unclear; some clinical trials stipulated
that they should be avoided during the trial. Given the current lack
of evidence, they should therefore be generally avoided.Management of infections during long-term FcRn
inhibition
Although bacterial respiratory tract infections are thought to be
the most likely consequence of FcRn inhibitors, any
infection should be thoroughly investigated to establish the
anatomical site and microbial etiology, and reported while
we gain experience with these agents. Reassessment of the
baseline immunologic parameters may also help to determine
any changes in immunophenotype that may be associated with the
infection.
Novel, rare, or recurring viral infections are always concerning.
Measles, influenza, and HBV are vaccination preventable and
immunity may be boosted before or during FcRn inhibition,
whereas for some other viruses, including the novel severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), at the time
of writing there exists no vaccine and no effective antiviral
treatment. A case report of nonsevere coronavirus disease 2019
(COVID-19) demonstrated recruitment of immune cell popula-
tions and IgM and IgG SARS-CoV-2-binding antibodies before
the resolution of symptoms.85 Although the primary antiviral
immune response involving IFNs, IgM, IgA, complement, and
natural killer and T cells is unlikely to be affected by FcRn
inhibition, the presence and the degree of low IgG levels and
the potential impact on the primary immune response when
exposed to a new virus or the clinical course and severity of
COVID-19 is unknown. It is therefore prudent to pause the
FcRn inhibitors if a diagnosis of COVID-19 or other severe respi-
ratory virus is confirmed, to mitigate against any consequences of
reduced IgG in this scenario.
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virus, and HIV is unknown but would be theorized to be favorable
to that of some other immunosuppressive options.
For patients with active viral infection (eg, detectable VL in
blood):d It may be prudent to initiate antiviral treatment before the
use of FcRn inhibitors.
d Monitor VL while on an FcRn inhibitor.
For chronic HBV (characterized by persistence of HBV surface
antigen:d Antiviral prophylaxis may be considered before and dur-
ing FcRn inhibition.
d HBV VL monitoring should be considered.
d Active monitoring (eg, with liver enzymes and HBV
VL), with preemptive initiation of antiviral therapy as
required.
d Possible referral to an infectious disease specialist.Key concepts and therapeutic implications
d Inhibition of FcRn is a promising therapeutic approach for the
treatment of IgG-mediated autoimmune diseases that has the po-
tential to provide an alternative to immunomodulatory high-dose
IVIg therapy, PLEX, IA, and other less targeted immunosuppres-
sive therapies.
d Successful treatment with an FcRn inhibitor will induce transientAppropriate antimicrobial therapy should be implemented if
needed—the choice dependent on severity of infection, anatom-
ical site, microbial etiology, local epidemiological pattern of
antimicrobial resistance, and, where possible, microbiological
sensitivities. For severe infections (ie, requiring hospitalization or
IV therapy), withholding any immunosuppressant treatment
should be considered; this decision likely also applies to FcRn
inhibition. In nonsevere cases, it is possible that FcRn inhibitors
can be continued with concomitant antimicrobial therapy and
close monitoring of IgG levels, particularly if the patient
demonstrates a favorable evolution. Where an FcRn inhibitor is
continued during or reinstituted after treatment of infection, close
monitoring for clinical and/or laboratory evidence of disease
recurrence is recommended. In cases of severe infection that
cannot be controlled with other specific treatments (eg, antibi-
otics), IgRT may be considered. Any subsequent decision about
continued FcRn inhibition would need to be based on individual
assessment of the patient, considering also any anticipated further
need for IgRT.
As with other novel biologic modulators, the emergence of
unanticipated side effects such as opportunistic infections should
be monitored in the real-world setting by building registries.
Opportunistic infections will need to be reported to the manu-
facturer and/or regulatory agency for safety purposes and the
cases published.low levels of IgG, including a lowering of IgG autoantibodies and
IgG-containing ICs.
d There are no anticipated effects of FcRn inhibitors on IgA, IgM,
IgE, complement, plasma cells, B cells, or other cells of the innate
or adaptive immune systems.
d Short-term treatment experiences with FcRn inhibitors currently
in development do not indicate an increased infection risk.Patients with primary or secondary immune
deficiency: Specific considerations
Patients who require IgRT because of primary or secondary
immune deficiency may be at risk of serious infections. FcRn
inhibition is unlikely to be appropriate for these patients.d Described treatment-related side effects of FcRn inhibitors are
headaches and mild GI symptoms (diarrhea, vomiting).Patients who have undergone splenectomy:
Specific considerations
Splenectomy remains a treatment option for patients with ITP
or common variable immune deficiency with severe autoimmune
cytopenias who have not responded to other therapies.86,87 In the
absence of any FcRn inhibitor–specific recommendations, stan-
dard guidelines for patients undergoing splenectomy88 should
be followed.Patients with splenectomy are at risk of overwhelming
postsplenectomy infection, a life-threatening sepsis. Where
overwhelming postsplenectomy infection develops despite
appropriate vaccination, chronic FcRn inhibitor therapy is
unlikely to be appropriate and alternative treatments for the
underlying condition should be considered.Monitoring during long-term FcRn inhibition
Postapproval, monitoring of patients receiving repeat cycles of
an FcRn inhibitor may include the following:
d A questionnaire-derived score to identify patients with
elevated risk of respiratory tract infections.89-92
d Measurement of incidence of infections, headache, and GI
symptoms; quality-of-life measures; body weight; and lab-
oratory data, including serum immunoglobulins and serum
albumin.SUMMARY AND CONCLUSIONS
Based on the evidence available to date, hypogamma-
globulinemia caused by FcRn blockade is transient and
reversible, and affects only the IgG isotype. Despite the
absence of data on specific vaccine and infection-induced
antibody titers before, during, and after FcRn blockade, we
do not expect that this inhibition impacts plasma cells or B
cells, or cells of the innate and adaptive immune systems.
By harnessing the IgG salvage and recycling pathway, FcRn
inhibitors have the potential to meet an urgent need for a
more targeted therapeutic approach to pathogenic IgG
reduction and provide a less invasive and time-consuming
alternative to PLEX, IA, and immunomodulatory high-dose
IVIg therapies.REFERENCES
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FIG E1. Impact of selected primary and secondary antibody deficiencies on IgG.E5-E85APRIL, A proliferation-
inducing ligand; BAFF, B-cell activating factor; BLyS, B-lymphocyte stimulator; DMARD, disease-modifying
antirheumatic drug; JAK, Janus kinase.
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TABLE E1. Summary of methodology for reported phase 2 clinical trials of FcRn inhibitors
Indication
No. of patients
randomized
Intervention and
comparator Primary end point Duration of follow-up
Geographical region
of recruited patients
Methodology for
infection screening
before enrollment Reported infections* Reference
Efgartigimod: IgG1 Fc fragment modified by 5 point mutations
MG
(NCT02965573)
24 IV efgartigimod 10
mg/kg QW vs
placebo
Safety and tolerability 11 wk Canada, Europe, US Exclusion criteria
d Active infection
d Recent serious
infection within
the 8 wk before
screening
d History of or
known infection
with HIV, HBV,
HCV, or TB
At screening patients
must have had nega-
tive test results for
d HBV surface
antigen
d HBV core
antibody
d HCV antibody
d HIV 1 and 2
antibodies
QuantiFERON-TB
Gold
Herpes zoster: 1
efgartigimod-
treated patient (also
on SoC treatment
with prednisone
and mycophenolate
mofetil)
E1
ITP
(NCT03102593)
38 IV efgartigimod 5 mg/
kg or 10 mg/kg,
QW (4 doses) vs
placebo
Safety and tolerability Main study: 21 wk
OLE: 1 y
Europe, Ukraine Not provided Pneumonia: 1
efgartigimod-
treated patient who
was deemed
unrelated to
treatment.
No increased risk of
infection was
apparent
E2
Rozanolixizumab: IgG4 mAb with a S241P stabilizing hinge mutation
MG
(NCT03052751)
43 Period 1: 3 doses of
SC
rozanolixizumab 7
mg/kg QW
Period 2: 3 doses of
SC
rozanolixizumab
4 mg/kg QW or
7 mg/kg QW
vs placebo
Clinically meaningful
improvements in
MG outcomes and
reductions in
autoantibody titers
Safety and tolerability
99 d Canada, Europe, US Not provided Not reported E3
(Continued)
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TABLE E1. (Continued)
Indication
No. of patients
randomized
Intervention and
comparator Primary end point Duration of follow-up
Geographical region
of recruited patients
Methodology for
infection screening
before enrollment Reported infections* Reference
ITP
(NCT02718716)
66 Single (15 or
20 mg/kg) or
multiple
(5 3 4 mg/kg,
3 3 7 mg/kg,
2 3 10 mg/kg
weekly)
doses of SC
rozanolixizumab;
total dose in each
group ranged from
15 to 21 mg/kg
No comparator
Safety and tolerability 12 wk Australia, Europe Exclusion criteria:
d Clinically relevant
active infection
d Serious infection
within 6 wk before
the first dose of
rozanolixizumab
No serious infections
were seen
E4
HCV, Hepatitis C virus; Ig, immunoglobulin; OLE, open-label extension; SoC, standard of care; TB, tuberculosis.
*Although neither FcRn inhibitor appears to increase in risk of infection, limitations of these data include small sample sizes and trial duration.
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